TY - JOUR
T1 - Angiographic evaluation of the effect of intracoronary abciximab administration in patients undergoing urgent PCI
AU - Romagnoli, Elisa
AU - Burzotta, Francesco
AU - Trani, Carlo
AU - Mazzari, Mario Attilio
AU - Biondi-Zoccai, Giuseppe G.L.
AU - De Vita, Maria
AU - Giannico, Floriana
AU - Niccoli, Giampaolo
AU - Prati, Francesco
AU - Rebuzzi, Antonio Giuseppe
AU - Mongiardo, Rocco
AU - Crea, Filippo
PY - 2005
Y1 - 2005
N2 - Background: Recent data suggest that the intracoronary (IC) administration of a systemic bolus dose of abciximab during PCI may increase the efficacy of this antiplatelet drug. However, the effect of IC abciximab on coronary angiographic flow has been not clarified. Methods: We studied 37 consecutive patients with acute coronary syndromes (ACS) who underwent successful urgent PCI on the target vessel and were treated by an IC abciximab bolus (0.25 mg/kg) prior to the first balloon inflation (Group IC), and 37 matched controls who were treated by intravenous (IV) abciximab bolus at the same dose (Group IV). Corrected TIMI frame count (CTFC) in the culprit and in a non-culprit coronary artery branch was assessed before treatment, immediately after intracoronary administration of abciximab bolus and at the end of the procedure. Results: After administration of abciximab, CTFC significantly decreased from 48 + 37 to 33 + 30 (P = 0.001) in the culprit vessel while in the non-culprit vessel it remained unchanged (16 + 7 pre-treatment and 16 + 7 post-treatment, P = 0.68). Final CTFC was 12 + 4 in Group IC and 14 + 5 in Group IV (P = 0.069). Post-treatment mean peak of the cardiac enzymes showed a trend toward reduction in Group IC compared with Group IV. Conclusions: The IC administration of abciximab bolus acutely decreases CTFC through culprit vessels of patients with ACS undergoing urgent PCI. Further studies evaluating the potential clinical benefits associated with IC abciximab administration are warranted. © 2005 Elsevier Ireland Ltd. All rights reserved.
AB - Background: Recent data suggest that the intracoronary (IC) administration of a systemic bolus dose of abciximab during PCI may increase the efficacy of this antiplatelet drug. However, the effect of IC abciximab on coronary angiographic flow has been not clarified. Methods: We studied 37 consecutive patients with acute coronary syndromes (ACS) who underwent successful urgent PCI on the target vessel and were treated by an IC abciximab bolus (0.25 mg/kg) prior to the first balloon inflation (Group IC), and 37 matched controls who were treated by intravenous (IV) abciximab bolus at the same dose (Group IV). Corrected TIMI frame count (CTFC) in the culprit and in a non-culprit coronary artery branch was assessed before treatment, immediately after intracoronary administration of abciximab bolus and at the end of the procedure. Results: After administration of abciximab, CTFC significantly decreased from 48 + 37 to 33 + 30 (P = 0.001) in the culprit vessel while in the non-culprit vessel it remained unchanged (16 + 7 pre-treatment and 16 + 7 post-treatment, P = 0.68). Final CTFC was 12 + 4 in Group IC and 14 + 5 in Group IV (P = 0.069). Post-treatment mean peak of the cardiac enzymes showed a trend toward reduction in Group IC compared with Group IV. Conclusions: The IC administration of abciximab bolus acutely decreases CTFC through culprit vessels of patients with ACS undergoing urgent PCI. Further studies evaluating the potential clinical benefits associated with IC abciximab administration are warranted. © 2005 Elsevier Ireland Ltd. All rights reserved.
KW - Abciximab
KW - Acute coronary syndromes
KW - Angina, Unstable
KW - Angioplasty, Balloon, Coronary
KW - Antibodies, Monoclonal
KW - Anticoagulants
KW - Coronary Angiography
KW - Emergency Treatment
KW - Female
KW - Humans
KW - Immunoglobulin Fab Fragments
KW - Injections, Intra-Arterial
KW - Male
KW - Middle Aged
KW - Myocardial Infarction
KW - Percutaneous coronary interventions
KW - Prospective Studies
KW - Abciximab
KW - Acute coronary syndromes
KW - Angina, Unstable
KW - Angioplasty, Balloon, Coronary
KW - Antibodies, Monoclonal
KW - Anticoagulants
KW - Coronary Angiography
KW - Emergency Treatment
KW - Female
KW - Humans
KW - Immunoglobulin Fab Fragments
KW - Injections, Intra-Arterial
KW - Male
KW - Middle Aged
KW - Myocardial Infarction
KW - Percutaneous coronary interventions
KW - Prospective Studies
UR - http://hdl.handle.net/10807/169784
U2 - 10.1016/j.ijcard.2004.11.037
DO - 10.1016/j.ijcard.2004.11.037
M3 - Article
SN - 0167-5273
VL - 105
SP - 250
EP - 255
JO - International Journal of Cardiology
JF - International Journal of Cardiology
ER -